Skip to main content

GeoVax Labs, Inc.

For the period ended Jun 30, 2026. Filed Jul 27, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Jul 27, 2026

GOVX$0.14-9.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 6. Exhibits

Exhibit
NumberDescription
3.2Certificate of Amendment to Certificate of Incorporation filed January 9, 2026 (2)
4.1Form of Pre-Funded Warrant, dated February 17, 2026 (3)
4.2Form of Series A-1 Common Warrant, dated February 17, 2026 (3)
4.3Form of Series A-2 Common Warrant, dated February 17, 2026 (3)
4.4Form of Warrant Amendment Agreement, dated February 17, 2026 (3)
4.5Form of Common Stock Purchase Warrant, dated March 31, 2026 (4)
4.6Form of Common Stock Purchase Warrant, dated May 8, 2026 (5)
4.7Form of Pre-Funded Warrant, dated May 19, 2026 (6)
4.8Form of Series A Common Warrant, dated May 19, 2026 (6)
4.9Form of Series B Common Warrant, dated May 19, 2026 (6)
10.1Securities Purchase Agreement, dated February 12, 2026 (3)
10.2Form of Inducement Letter, dated March 31, 2026 (4)
10.3Form of Inducement Letter, dated May 7, 2026 (5)
10.4Form of Purchase Agreement, dated May 18, 2026 (6)
10.5Form of Placement Agency Agreement between the Company and A.G.P./Alliance Global Partners (6)
31.1*Certification pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934
31.2*Certification pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934
32.1*Certification pursuant to 18 U.S.C. Section 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002
32.2*Certification pursuant to 18 U.S.C. Section 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002
101.INSInline XBRL Instance Document (1)
101.SCHInline XBRL Taxonomy Extension Schema Document (1)
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document (1)
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document (1)
101.LABInline XBRL Taxonomy Extension Label Linkbase Document (1)
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document (1)
104Inline XBRL for the cover page of this Quarterly Report on Form 10-Q and included in the Exhibit 101 Inline XBRL Document Set (1)
*Filed herewith
**Indicates a management contract or compensatory plan or arrangement
(1)These interactive data files shall not be deemed filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, or Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under these sections.
(2)Incorporated by reference from the registrant’s Current Report on Form 8-K filed January 12, 2026.
(3)Incorporated by reference from the registrant’s Current Report on Form 8-K filed February 17, 2026.
(4)Incorporated by reference from the registrant’s Current Report on Form 8-K filed March 31, 2026.
(5)Incorporated by reference from the registrant’s Current Report on Form 8-K filed May 7, 2026.
(6)Incorporated by reference from the registrant’s Current Report on Form 8-K filed May 19, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this quarterly report on Form 10-Q to be signed on its behalf by the undersigned thereunto duly authorized.

GEOVAX LABS, INC. (Registrant)
Date: July 27, 2026By:/s/ Mark W. Reynolds
Mark W. Reynolds
Chief Financial Officer (duly authorized officer and principal financial officer)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.